Overview

An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This large, non-randomized observational study is being conducted to provide data about the impact of ethnic origin on outcomes and resource utilization during the 2nd line treatment of non-small cell lung cancer (NSCLC) in a routine medical care setting.
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Pemetrexed